Wolff Stefani
Known title: EVP and COOCIK: 0001751790
Associated companies
Transaction History
| NRIX | ▼ Sell | Open Market | 342 | $3K | 5/1/2023 | View on chart |
| NRIX | ▲ Buy | Option Exercise | 962 | $0 | 4/30/2023 | View on chart |
| NRIX | ▲ Buy | Option Exercise | 962 | $0 | 1/30/2023 | View on chart |
| NRIX | ▼ Sell | Open Market | 424 | $5K | 1/30/2023 | View on chart |
| NRIX | ▼ Sell | Open Market | 350 | $5K | 10/31/2022 | View on chart |
| NRIX | ▲ Buy | Option Exercise | 962 | $0 | 10/30/2022 | View on chart |
| NRIX | ▼ Sell | Open Market | 356 | $6K | 8/1/2022 | View on chart |
| NRIX | ▲ Buy | Option Exercise | 962 | $0 | 7/30/2022 | View on chart |
| NRIX | ▼ Sell | Open Market | 330 | $4K | 5/2/2022 | View on chart |
| NRIX | ▲ Buy | Option Exercise | 962 | $0 | 4/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Nurix Advances Bexobrutideg Studies and Secures $10M Gilead Extension
Nurix has enrolled its first patient in a Phase 1b/2 study of Bexobrutideg for chronic lymphocytic leukemia, and a second enrollment began for a Bexobrutideg plus Venetoclax combination under a Roche partnership. The company also received a second research term extension for its oncology program with Gilead Sciences and secured $10 million from Gilead as part of the extended drug‑discovery collaboration. These developments show ongoing progress in Nurix’s pipeline and continued partnership support.
Nurix Advances Bexobrutideg Studies and Secures $10M Gilead Extension. Nurix has enrolled its first patient in a Phase 1b/2 study of Bexobrutideg for chronic lymphocytic leukemia, and a second enrollment began for a Bexobrutideg plus Venetoclax combination under a Roche partnership. The company also received a second research term extension for its oncology program with Gilead Sciences and secured $10 million from Gilead as part of the extended drug‑discovery collaboration. These developments show ongoing progress in Nurix’s pipeline and continued partnership support.